26PD - An innovative technology for in vivo isolation of circulating tumor cells in non-small cell lung cancer (NSCLC) patients and immunofluorescent detec...

Date 27 March 2014
Event ELCC 2014
Session Poster Discussion 1
Topics Non-Small-Cell Lung Cancer, Metastatic
Translational Research
Presenter Barbara Dlugaszewska
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors B. Dlugaszewska1, L. Gasiorowski2, S. Herold1, B. Nowack3, G. Dworacki4, K. Luecke5, W. Dyszkiewicz2
  • 1Ks, GILUPI GmbH, 14476 - Potsdam/DE
  • 2Department Of Thoracic Surgery, University of Medical Sciences, Poznan/PL
  • 3R&d, GILUPI GmbH, 14476 - Potsdam/DE
  • 4Department Of Clinical Immunology, University of Medical Sciences, Poznan/PL
  • 5Gm, GILUPI GmbH, 14476 - Potsdam/DE



Circulating tumor cells (CTCs) in lung cancer patients can provide additional information on patient prognosis and treatment efficacy. Currently, CTCs are isolated in vitro from limited volumes of patient blood samples. To overcome this limitation, an innovative device, Detektor CANCER01 (DC01), was used to isolate CTCs in vivo, directly from the bloodstream of lung cancer patients.